Skip Navigation


NDT Advance Access originally published online on November 28, 2007
Nephrology Dialysis Transplantation 2008 23(2):751-756; doi:10.1093/ndt/gfm675
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/2/751    most recent
gfm675v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kinomura, M.
Right arrow Articles by Makino, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kinomura, M.
Right arrow Articles by Makino, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


A novel variant apolipoprotein E Okayama in a patient with lipoprotein glomerulopathy

Masaru Kinomura1, Hitoshi Sugiyama1, Takao Saito2, Akira Matsunaga3, Ken-ei Sada1, Motoko Kanzaki1, Yuki Takazawa1, Yohei Maeshima1, Hiroyuki Yanai4 and Hirofumi Makino1

1Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan, 2Division of Nephrology and Rheumatology, Fukuoka University School of Medicine, Fukuoka, Japan, 3Division of Cardiology, Department of Internal Medicine, Fukuoka University School of Medicine, Fukuoka, Japan and 4Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan

Correspondence and offprint requests to: Hitoshi Sugiyama, Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan. Tel: +81-86-235-7235; Fax: +81–86-222-5214; E-mail: hitoshis@md.okayama-u.ac.jp

Keywords: apolipoprotein E; fibrate; hyperlipidemia; proteinuria; renal lipidosis

The first 150 words of the full text of this article appear below.



   Introduction
 
Lipoprotein glomerulopathy (LPG) is a rare disorder characterized by lipoprotein thrombi in the intraglomerular capillaries and high serum concentrations of apolipoprotein E (apoE). In 1989, Saito et al. [2,3]. Patients with LPG usually present with nephrotic syndrome and a relatively rapid progression to end-stage renal failure.

Human apoE is composed of 299 amino acids and mediates tissue uptake of triglyceride-rich lipoproteins through both low-density lipoprotein (LDL) receptor and LDL-receptor-related protein pathways. Genetic variations at the apoE gene locus code for three different major isoforms designated E2, E3 and E4, representing their migration characteristics of isoelectric focusing (IEF). The wild-type allele is apoE3, while apoE2 (Arg158Cys) and apoE4 (Cys112Arg) are less common. ApoE3 and apoE4 are thought to bind equally to the lipoprotein receptors, whereas apoE2 is defective in its lipoprotein receptor binding [4]. Homozygosity for apoE2 (Arg158Cys) results in the development of type . . . [Full Text of this Article]



   Case report
 
Pathologic findings
Phenotype, genotype and DNA sequence analysis of apoE
Clinical course


   Supplementary Data
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?